On November 3, 2021 Philogen reported that Dario Neri, co-founder, CEO and CSO, is giving a presentation focused on Tripokin, a novel fusion protein capable of an exceptionally selective uptake at the tumor site (Press release, Philogen, NOV 3, 2021, View Source [SID1234594675]). The product contains two highly synergistic cytokine moieties (interleukin-2 and tumor necrosis factor) fused to the L19 antibody, specific to the alterantively-spliced EDB domain of fibronectin. In the seminar, Dario Neri is presenting the discovery and development of Tripokin towards clinical trials in patients with different types of cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!